Physician profile
Komal Hargovind Ashraf
NPI 1457580490
$202,355.04
in general payments reported to CMS, 2019-2025
40 companies · $39K in 2025
The $39K reported for 2025 was more than what 97% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $14K · 2021: $26K · 2022: $36K · 2023: $25K · 2024: $48K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Travel and Lodging: $9,955 · Consulting Fee: $9,740 · Food and Beverage: $8,728 · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,521.25 |
| Travel and Lodging | $9,955.41 |
| Consulting Fee | $9,740.00 |
| Food and Beverage | $8,727.96 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $91,118.41 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Abbvie INC. | $55,236.29 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Sk Life Science, INC. | $35,593.61 | 2020-2025 | Xcopri |
| Livanova USA, INC. | $13,086.61 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Jazz Pharmaceuticals INC. | $1,503.54 | 2019-2025 | |
| Greenwich Biosciences, INC. | $1,153.28 | 2019-2021 | |
| Medtronic, INC. | $531.83 | 2021-2025 | Percept Pc Brainsense, Activa Pc |
| Novartis Pharmaceuticals Corporation | $497.45 | 2019-2024 | |
| Eisai INC. | $400.83 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $365.41 | 2023-2024 | Nuedexta |
| Biogen, INC. | $351.95 | 2021-2024 | Vumerity, Tysabri |
| Catalyst Pharmaceuticals, INC. | $235.22 | 2019-2025 | Fycompa |
| Genzyme Corporation | $220.91 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $215.90 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $205.10 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Komal Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.